表紙
市場調查報告書

各前列腺癌症診斷的全球市場:各類型(預備檢驗,確認檢驗) 市場分析與預測 2018年∼2025年

Prostate Cancer Diagnostics Market Analysis Report By Type (Preliminary Tests, Confirmatory Tests), By Region (North America, APAC, Europe, MEA, Latin America), And Segment Forecasts, 2018 - 2025

出版商 Grand View Research, Inc. 商品編碼 726439
出版日期 內容資訊 英文 75 Pages
商品交期: 2-3個工作天內
價格
Back to Top
各前列腺癌症診斷的全球市場:各類型(預備檢驗,確認檢驗) 市場分析與預測 2018年∼2025年 Prostate Cancer Diagnostics Market Analysis Report By Type (Preliminary Tests, Confirmatory Tests), By Region (North America, APAC, Europe, MEA, Latin America), And Segment Forecasts, 2018 - 2025
出版日期: 2018年08月16日內容資訊: 英文 75 Pages
簡介

全球前列腺癌症診斷市場在2018年到2025年間,預測將以12.3%的年複合成長率發展,到2025年市場規模將成長到55億美元。由於前列腺癌症的盛行率的上升,持續性技術進步等促進該市場成長。

本報告提供全球前列腺癌症診斷市場調查,市場概要,各類型、各地區的市場規模的變化與預測,市場趨勢,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 調查方法

  • 資訊採購
  • 資料分析

第2章 摘要整理

  • 市場概述

第3章 市場變數,市場趨勢,範圍

  • 市場區隔和範圍
  • 普及與成長預測製圖
  • SWOT分析(從政治、法律、經濟、技術的觀點)
  • 波特的五力分析

第4章 前列腺癌症診斷市場分析:各類型

  • 市場趨勢分析:各類型
  • 預備檢驗
  • 確認檢驗
    • PCA3檢驗
    • 經直腸的超音波檢驗
    • 切片檢查

第5章 前列腺癌症診斷市場分析:各地區

  • 市場趨勢分析:各地區
  • 市場佔有率:各地區(成果值、預測值)
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第6章 競爭情形

  • 策略架構
  • 企業簡介
    • MDxHealth
    • 3D Signatures
    • Genomic Health
    • Abbott
    • OPKO Health, Inc.
    • Siemens Healthcare GmbH
    • DiaSorin S.p.A.
    • bioMerieux SA
    • F. Hoffman La Roche Ltd.
    • Beckman Coulter, Inc.
    • Myriad Genetic, Inc.
目錄
Product Code: GVR-2-68038-548-9

The global prostate cancer diagnostics market size is expected to reach USD 5.5 billion by 2025, according to a new report by Grand View Research, Inc. The market is estimated to expand at a CAGR of 12.3% during the forecast years. Demand for prostate cancer diagnostics is increasing owing to rising prevalence of the disease along with constant technological advancements and awareness regarding the same.

Every year, more than 2,30,000 men are diagnosed with prostate cancer. In addition, as per a study conducted by the American Cancer Society, prostate cancer is the third leading cause of cancer-related deaths in U .S. Constant development of new technologies for the disease diagnosis and treatment would drive the market over the coming years.

Magnetic Resonance Imaging (MRI) technology and Fusion biopsy are the new technologies used for the disease diagnosis. Fusion biopsy is a technique, which uses the combination of MRI and ultrasound. Some of the leading companies in the prostate cancer diagnostics market are MDx Health; Abbott Laboratories; Siemens Healthcare GmbH; F. Hoffman-La Roche AG; Myriad Genetics, Inc.; Genomic Health; and OPKO Health, Inc.

Further key findings from the study suggest:

  • Increasing prevalence of prostate cancer is primarily boosting the market growth across the globe
  • Growing awareness regarding the disease and available treatments along with supportive government initiatives would also drive the market
  • The preliminary tests segment captured the largest market share of prostate cancer diagnostics in 2016
  • Confirmatory tests segment is said to expand at the fastest CAGR due to low risk of infection, convenience, and non-invasive nature of these tests
  • North America is dominant regional market followed by Europe due to sophisticated healthcare infrastructure and availability of technologically advanced products

Key companies in the market include: MDx Health; Abbott Laboratories; Siemens Healthcare GmbH; F. Hoffman-La Roche AG; Myriad Genetics, Inc.; Genomic Health; and OPKO Health, Inc.

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Information procurement
  • 1.2 Information or Data Analysis
    • 1.2.1 Market Formulation & Validation
  • 1.3 Region Wise Market Calculation
    • 1.3.1 Region Wise Market: Base Estimates
    • 1.3.2 Global Market: CAGR Calculation

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Prostate Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1 Market segmentation & scope
    • 3.1.1 Market Driver Analysis
      • 3.1.1.1 Increasing prevalence of prostate cancer
      • 3.1.1.2 Increasing government initiatives
      • 3.1.1.3 Technological advancements
    • 3.1.2 Market Restraint Analysis
      • 3.1.2.1 High cost of diagnosis
  • 3.2 Penetration & growth prospect mapping
  • 3.3 Prostate Cancer Diagnostics - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 3.4 Industry Analysis - Porter's

Chapter 4 Prostate Cancer Diagnostics Market: Type Estimates & Trend Analysis

  • 4.1 Prostate cancer diagnostics market: Type movement analysis
  • 4.2 Preliminary Tests
  • 4.3 Confirmatory Tests
    • 4.3.1. Confirmatory Tests Market Estimates & Segment Forecast, 2014 - 2025 (USD Million)
    • 4.3.2 PCA3Test
      • 4.3.2.1 PCA3Test Market, 2014 - 2025 (USD Million)
    • 4.3.3 Trans-rectal ultrasound
      • 4.3.3.1 Trans-rectal ultrasound Market, 2014 - 2025 (USD Million)
    • 4.3.4 Biopsy
      • 4.3.4.1 Biopsy Market, 2014 - 2025 (USD Million)

Chapter 5 Prostate Cancer Diagnostics Market: Regional Estimates & Trend Analysis, by Type

  • 5.1 Prostate Cancer Diagnostics Market: Regional Movement Analysis
  • 5.2 Prostate cancer diagnostics market share by region, 2015 & 2025
  • 5.3 North America
    • 5.3.1 North America market, 2014 - 2025 (USD Million)
    • 5.3.2 U.S.
      • 5.3.2.1 U.S. market, 2014 - 2025 (USD Million)
    • 5.3.3 Canada
      • 5.3.3.1 Canada market, 2014 - 2025 (USD Million)
  • 5.4 Europe
    • 5.4.1 Europe market, 2014 - 2025 (USD Million)
    • 5.4.2 U.K.
      • 5.4.2.1 U.K. market, 2014 - 2025 (USD Million)
    • 5.4.3 Germany
      • 5.4.3.1 Germany market, 2014-2025 (USD Million)
  • 5.5 Asia Pacific
    • 5.5.1 Asia Pacific market, 2014 - 2025 (USD Million)
    • 5.5.2 Japan
      • 5.5.2.1 Japan market, 2014 - 2025 (USD Million)
    • 5.5.3 China
      • 5.5.3.1 China market, 2014 - 2025 (USD Million)
  • 5.6 Latin America
    • 5.6.1 Latin America market, 2014 - 2025 (USD Million)
    • 5.6.2 Brazil
      • 5.6.2.1 Brazil market, 2014 - 2025 (USD Million)
    • 5.6.3 Mexico
      • 5.6.3.1 Mexico market, 2014 - 2025 (USD Million)
  • 5.7 MEA
    • 5.7.1 MEA market, 2014 - 2025 (USD Million)
    • 5.7.2 South Africa
      • 5.7.2.1 South Africa market, 2014 - 2025 (USD Million)

Chapter 6 Competitive Landscape

  • 6.1 Strategy framework
  • 6.2 Company Profiles
    • 6.2.1 MDxHealth
      • 6.2.1.1 Company overview
      • 6.2.1.2 Financial performance
      • 6.2.1.3 Product benchmarking
      • 6.2.1.4 Strategic initiatives
    • 6.2.2 3D Signatures
      • 6.2.2.1 Company overview
      • 6.2.2.2 Product benchmarking
      • 6.2.2.3 Strategic initiatives
    • 6.2.3 Genomic Health
      • 6.2.3.1 Company overview
      • 6.2.3.2 Financial Performance
      • 6.2.3.3 Product Benchmarking
      • 6.2.3.4 Strategic initiatives
    • 6.2.4 Abbott
      • 6.2.4.1 Company overview
      • 6.2.4.2 Financial performance
      • 6.2.4.3 Product benchmarking
    • 6.2.5 OPKO Health, Inc.
      • 6.2.5.1 Company overview
      • 6.2.5.2 Financial performance
      • 6.2.5.3 Product benchmarking
    • 6.2.6 Siemens Healthcare GmbH
      • 6.2.6.1 Company overview
      • 6.2.6.2 Financial Performance
      • 6.2.6.3 Product benchmarking
    • 6.2.7 DiaSorin S.p.A.
      • 6.2.7.1 Company overview
      • 6.2.7.2 Financial performance
      • 6.2.7.3 Product benchmarking
      • 6.2.7.4 Strategic initiatives
    • 6.2.8 bioMerieux SA
      • 6.2.8.1 Company overview
      • 6.2.8.2 Financial performance
      • 6.2.8.3 Product benchmarking
    • 6.2.9 F. Hoffman La Roche Ltd.
      • 6.2.9.1 Company overview
      • 6.2.9.2 Financial performance
      • 6.2.9.3 Product benchmarking
      • 6.2.9.4 Strategic initiatives
    • 6.2.10 Beckman Coulter, Inc.
      • 6.2.10.1 Company overview
      • 6.2.10.2 Financial performance
      • 6.2.10.3 Product benchmarking
    • 6.2.11 Myriad Genetic, Inc.
      • 6.2.11.1 Company overview
      • 6.2.11.2 Financial performance
      • 6.2.11.3 Product benchmarking
      • 6.2.11.4 Strategic Initiatives

List of Tables

  • TABLE 1 North America Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 2 U.S. Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 3 Canada Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 4 Europe Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 5 Germany Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 6 U.K. Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 7 Asia-Pacific Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 8 Japan Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 9 China Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 10 Latin America Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 11 Brazil Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 12 Mexico Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 13 Middle East & Africa Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)
  • TABLE 14 South Africa Prostate Cancer Diagnostics market revenue, by Type, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Market summary (USD Million), 2015
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Market restraint relevance analysis (Current & future impact)
  • FIG. 12 Penetration & growth prospect mapping
  • FIG. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 14 Porter's Five Forces Analysis
  • FIG. 15 Prostate Cancer Diagnostics market: Type outlook key takeaways
  • FIG. 16 Prostate Cancer Diagnostics: Type Movement Analysis, USD Million
  • FIG. 17 Preliminary Tests Market, 2014 - 2025 (USD Million)
  • FIG. 18 Confirmatory Tests Market, 2014 - 2025 (USD Million)
  • FIG. 19 PCA3Test Market, 2014 - 2025 (USD Million)
  • FIG. 20 Trans-rectal ultrasound Market, 2014 - 2025 (USD Million)
  • FIG. 21 Biopsy Market, 2014 - 2025 (USD Million)
  • FIG. 22 Regional market place: Key takeaways
  • FIG. 23 Prostate Cancer Diagnostics Market: Regional Movement Analysis, USD Million
  • FIG. 24 North America market, 2014 - 2025 (USD Million)
  • FIG. 25 U.S. market, 2014 - 2025 (USD Million)
  • FIG. 26 Canada market, 2014 - 2025 (USD Million)
  • FIG. 27 Europe market, 2014 - 2025 (USD Million)
  • FIG. 28 U.K. market, 2014 - 2025 (USD Million)
  • FIG. 29 Germany market, 2014 - 2025 (USD Million)
  • FIG. 30 Asia Pacific market, 2014 - 2025 (USD Million)
  • FIG. 31 Japan market, 2014 - 2025 (USD Million)
  • FIG. 32 China market, 2014 - 2025 (USD Million)
  • FIG. 33 Latin America market, 2014 - 2025 (USD Million)
  • FIG. 34 Brazil market, 2014 - 2025 (USD Million)
  • FIG. 35 Mexico market, 2014 - 2025 (USD Million)
  • FIG. 36 MEA market, 2014 - 2025 (USD Million)
  • FIG. 37 South Africa market, 2014 - 2025 (USD Million)
  • FIG. 38 Strategy framework
Back to Top